My name is Debika Kundu and I am currently a P3 student pharmacist. On campus, I serve as the President of the American Pharmacists Association – Academy of Student Pharmacists (APhA-ASP) and a LEADS mentor for the Rho Chi Honor Society. I also work as an intern pharmacist at New York-Presbyterian Hospital/Columbia University Irving Medical Center and Calvary Hospital.

I am interested in pursuing clinical pharmacy because I want to directly contribute to patient care by collaborating with physicians, nurses, and other integral members of the interdisciplinary team. I want to apply my six years of education to real-life patient cases and continue expanding my knowledge. As a clinical pharmacist, I would also strive to achieve BCPS certification and precept students and residents.

I have recently had more time to start reading again! My favorite genres include mystery, thriller, historical fiction, and self-help books. Besides reading, I also love going to movie theaters, doing Pilates, and exploring new cafes.

eMAR

Recent Posts

Oxidative Stress and Its Impact on Vitiligo

By: Zurriya Faran, PharmD Candidate c/o 2031 The visible loss of skin pigmentation often indicates…

2 months ago

Thiamine Metabolic Dysfunction Syndrome: Overview, importance, MOA, and treatment

By: Archana Murugan, PharmD candidate c/o 2029 Overview             Thiamine metabolic dysfunction syndrome (TMDS) refers…

2 months ago

Updated Guidelines for the Treatment of Multidrug and Rifampin-Resistant TB and Promising New Anti-TB Drugs in Phase 2/3 Trials

By: Kevin Lee, PharmD Candidate c/o 2028, Angela Yin, PharmD Candidate c/o 2028             The…

2 months ago

Sixth Year Perspective: Interview with Ariella Zadrima, PharmD Candidate, c/o 2026

By: Aymon Choudhury, PharmD Candidate c/o 2027 APPE questions: How did your APPE rotations shape…

2 months ago

Foundayo: The New Drug in the GLP-1 market

By: Sariah Grant, PharmD Candidate c/o 2027             The rise of glucagon-like peptide -1 receptor…

2 months ago

Should All Drugs be OTC? Risks and Consequences of the FDA Commissioner Statement

By: Amanda Kastel, PharmD Candidate c/o 2027 In February 2026, FDA Commissioner Marty Makary stated…

2 months ago